About
Shaomeng Wang is a Warner-Lambert/Parke-Davis Professor of Medicine, Medical Director, and holds professorships in Internal Medicine, Pharmacology, and Medicinal Chemistry at the University of Michigan's Medical School and College of Pharmacy. He specializes in cancer biology, pharmacology, and drug development with a focus on molecular degraders like PROTACs. His research includes developing therapies targeting MDM2, STAT proteins, and androgen receptors for cancers such as breast, prostate, and pancreatic cancers. He leads projects at the Rogel Cancer Center and Center for Computational Medicine and Bioinformatics. Recent work includes novel degraders for IKZF2, SMARCA2, and CBP/p300, demonstrating efficacy in tumor regression and immunotherapy. His publications emphasize translational research bridging basic science and clinical applications.
- Education: PhD in relevant field (not explicitly stated in text)
- Affiliations: Medical School, College of Pharmacy, Rogel Cancer Center, Center for Computational Medicine and Bioinformatics (CCMB)
- Grants/Projects: Multiple NIH-funded projects on molecular degraders (implied via publication outputs)
- Labs/Teams: Leads drug discovery teams focusing on cancer immunotherapy and targeted therapies
Research interests emphasize molecular mechanisms of cancer progression, development of targeted therapies, and PROTAC-based degraders to overcome drug resistance. Recent studies highlight tumor microenvironment modulation and immune checkpoint strategies.
